<DOC>
	<DOC>NCT00104130</DOC>
	<brief_summary>The purpose of this trial is to study KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen.</brief_summary>
	<brief_title>Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer</brief_title>
	<detailed_description>This study is a Phase 2, single arm study of KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen. PSA response is the primary end-point and objective responses will be checked as available.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>At least 18 years of age. Metastatic disease. One previous treatment including docetaxel (Taxotere). At least 3 weeks since last surgery/radiation/chemotherapy ECOG Performance Status of 0, 1 or 2 Active brain metastases</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>prostate</keyword>
</DOC>